NLS New Market

The European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents and adults with haemophilia A.

Nexstim’s business partner PO Medica AB has sold two Navigated Brain Therapy (NBT) systems to two different hospitals Sweden. Both hospitals will be the first in Sweden to have the NBT systems and it will be their first time using navigated Transcranial Magnetic Stimulation (TMS) for the treatment of MDD. The systems will be used for the […]

The company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s GARD technology platform, it states. Using genetic biomarkers, GARDair tests whether substances and chemicals […]

The company reports first sales in Austria for its CADScor System for early rule-out of CAD. “By using the unique technology provided by Acarix and the CADScor System I can limit the number of patients that will be referred to coronary angiography. This will help shorten waiting lists and add value for both patients and the healthcare system. […]

The company announced in June that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU. The launch is triggering a milestone payment of EUR 3 million (approx. SEK 30.6 million) from Mundipharma, reports the company. “Taking the step out in […]

The company has registered Dignitana S.r.l as a new entity in Italy, a wholly-owned subsidiary of Dignitana AB. The entity will function under the leadership of Dignitana AB and with this registration the company can now finalize contracts for the sale of 3 machines in Italy. “We are excited to announce the registration of Dignitana S.r.l […]